Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic.

Anton Reepalu; Taye Balcha; Tadele Yitbarek; Godana Jarso; Erik Sturegård; Per Björkman

doi:10.1186/s13104-015-1707-6

Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic.

Anton Reepalu, Taye Balcha, Tadele Yitbarek, Godana Jarso, Erik Sturegård, Per Björkman

Clinical Microbiology, Malmö

Research output: Contribution to journal › Article › peer-review

Abstract

Since treatment for latent cryptococcal infection (CI) before starting antiretroviral therapy (ART) reduces mortality in HIV-infected subjects, screening for cryptococcal antigen (CrAg) in blood is recommended for individuals with CD4 cell counts < 100 cells/µL in regions with high CI prevalence. We assessed CrAg screening using the lateral flow assay in HIV-infected adults eligible for ART in central Ethiopia.

Original language	English
Article number	702
Journal	BMC Research Notes
Volume	8
Issue number	1
DOIs	https://doi.org/10.1186/s13104-015-1707-6
Publication status	Published - 2015

Subject classification (UKÄ)

Infectious Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13104-015-1707-6

http://www.ncbi.nlm.nih.gov/pubmed/26597840?dopt=Abstract

Cite this

@article{33c1e69b301445df80fddf2fb8a502a8,

title = "Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-na{\"i}ve HIV-positive adults at an Ethiopian hospital clinic.",

abstract = "Since treatment for latent cryptococcal infection (CI) before starting antiretroviral therapy (ART) reduces mortality in HIV-infected subjects, screening for cryptococcal antigen (CrAg) in blood is recommended for individuals with CD4 cell counts < 100 cells/µL in regions with high CI prevalence. We assessed CrAg screening using the lateral flow assay in HIV-infected adults eligible for ART in central Ethiopia.",

author = "Anton Reepalu and Taye Balcha and Tadele Yitbarek and Godana Jarso and Erik Stureg{\aa}rd and Per Bj{\"o}rkman",

year = "2015",

doi = "10.1186/s13104-015-1707-6",

language = "English",

volume = "8",

journal = "BMC Research Notes",

issn = "1756-0500",

publisher = "BioMed Central (BMC)",

number = "1",

}

TY - JOUR

T1 - Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic.

AU - Reepalu, Anton

AU - Balcha, Taye

AU - Yitbarek, Tadele

AU - Jarso, Godana

AU - Sturegård, Erik

AU - Björkman, Per

PY - 2015

Y1 - 2015

N2 - Since treatment for latent cryptococcal infection (CI) before starting antiretroviral therapy (ART) reduces mortality in HIV-infected subjects, screening for cryptococcal antigen (CrAg) in blood is recommended for individuals with CD4 cell counts < 100 cells/µL in regions with high CI prevalence. We assessed CrAg screening using the lateral flow assay in HIV-infected adults eligible for ART in central Ethiopia.

AB - Since treatment for latent cryptococcal infection (CI) before starting antiretroviral therapy (ART) reduces mortality in HIV-infected subjects, screening for cryptococcal antigen (CrAg) in blood is recommended for individuals with CD4 cell counts < 100 cells/µL in regions with high CI prevalence. We assessed CrAg screening using the lateral flow assay in HIV-infected adults eligible for ART in central Ethiopia.

U2 - 10.1186/s13104-015-1707-6

DO - 10.1186/s13104-015-1707-6

M3 - Article

C2 - 26597840

SN - 1756-0500

VL - 8

JO - BMC Research Notes

JF - BMC Research Notes

IS - 1

M1 - 702

ER -

Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this